From an outside perspective, the American cannabis industry has always been a contradiction. It combines deep cultural roots and commercial brilliance, but under a fragmented legal framework that complicates even the basics. Changes come frustratingly slow, despite years of debate and efforts to improve the system to secure everything from medical research to safe banking. The potential rescheduling of cannabis in the United States could be a pivotal, long-overdue moment, not only for American stakeholders but also for foreign companies exploring the transatlantic market. For international operators, rescheduling is more than a regulatory update — it represents a potential green light.
There’s a lot to entice non-American companies to the U.S. market. New states frequently update their cannabis policies to increase access, while brands and dispensaries are sleek and professional, contributing to a multi-billion-dollar industry that has only existed in this form for a decade.
It’s well known, though, that behind this vibrant surface lies a deeply inconsistent regulatory environment. The state-by-state patchwork creates friction for businesses and investors, limiting scalability and slowing innovation for any operator, but especially for those not embedded in the day-to-day nuances of state policy, commerce, and culture.
Without rescheduling, the U.S. cannabis industry will remain trapped in its own contradictions for both domestic and foreign operators alike. For the latter, it would bring much-needed hope about investing in American operations. The broader political climate has raised concerns for many European companies. Frequent and often unpredictable policy changes, tariffs, and international volatility have made it difficult to plan long-term investments.
Trade tariffs are a clear example of the challenges. American consumers consistently express interest in affordable quality, but antagonistic policies have made products more expensive. For cannabis companies, which already operate with tight margins, these added pressures make transatlantic ventures all but …
Read More
Author: Nick Avé / High Times
